Evaluation of Rasburicase Use in the Fraser Health Authority: A Retrospective Review
Bibliographic record
Abstract
ABSTRACTBackground: Rasburicase, a recombinant urate oxidase, is restricted in the Fraser Health Authority (FHA) to the “treatment of acute or at high risk of tumour lysis syndrome [TLS], when other therapeutic options are not suitable”. The manufacturer’s recommended dosage is 0.2 mg/kg daily for up to 7 days. Given the high cost of this drug, several studies have investigated other strategies and found that a single dose, repeated as needed, is effective in reducing serum uric acid. However, there are currently no guidelines in FHA for the use of rasburicase, which may result in different prescribing practices within the health authority.Objectives: To describe the prescribing of rasburicase in FHA, including indications and doses, and to report the uric acid–lowering effects of rasburicase and any clinical outcomes, such as dialysis or death.Methods: This retrospective descriptive chart review included adult patients receiving care in FHA for whom rasburicase was prescribed between June 1, 2010, and November 30, 2016. Descriptive statistics were used to summarize patient characteristics and results.Results: The prescribing practices for rasburicase in this health authority were largely inconsistent, but the most common dose administered was 3 mg (8/12 [67%] among those receiving rasburicase for prophylaxis and 9/32 [28%] among those receiving rasburicase for treatment; combined total 17/44 or 39%). Regardless of dose, rasburicase reduced serum uric acid levels to less than 476 µmol/L and decreased the risk of TLS. Conclusions: Having a uniform approach—involving a single dose that can be repeated as needed—for prevention and treatment of elevated serum uric acid levels could result in sufficient reduction of uric acid levels with fewer doses and lower cost. The results of this study support the need for a resource in FHA to guide and standardize the use of rasburicase.RÉSUMÉContexte : La Fraser Health Authorty limite l’usage de la rasburicase, une urate oxydase recombinée, au « traitement du syndrome de lyse tumorale (SLT) aigu ou comportant un risque élevé, lorsque les autres options thérapeutiques ne conviennent pas ». Le fabricant recommande une dose quotidienne de 0,2 mg/kg pendant une durée allant jusqu’à sept jours. Étant donné le coût élevé de ce médicament, plusieurs études ont exploré d’autres stratégies et ont permis de conclure qu’une dose unique, répétée au besoin, était efficace pour réduire le taux sérique d’acide urique. Cependant, il n’existe actuellement aucune ligne directrice provenant du Fraser Health relative à l’utilisation de la rasburicase, ce qui pourrait entraîner des pratiques différentes en matière de prescription au sein de l’institution.Objectifs : Décrire la prescription de rasburicase au Fraser Health, y compris les indications et les doses, et rapporter les effets réducteurs de l’acide urique de la rasburicase et tout autre résultat clinique, comme la dialyse ou la mort.Méthodes : Cet examen rétrospectif et descriptif des dossiers comprenait des patients adultes soignés au Fraser Health, qui avaient reçu une prescription de rasburicase entre le 1er juin 2010 et le 30 novembre 2016. Le résumé des caractéristiques des patients et des résultats de l’étude a été obtenu à l’aide de statistiques descriptives.Résultats : Les pratiques en matière de prescription de la rasburicase au Fraser Health étaient largement incohérentes, mais la dose la plus communément administrée aux personnes recevant de la rasburicase en prophylaxie était de 3 mg (8/12 [67 %] alors que 9/32 [28 %] des personnes recevaient la même dose comme traitement, donc un total combiné de 17/44 ou 39 %). Quelle que soit la dose, la rasburicase réduisait le taux sérique d’acide urique à moins de 476 µmol/L et diminuait le risque de SLT. Conclusions : L’adoption d’une approche uniforme—impliquant une dose unique pouvant être répétée au besoin—pour la prévention et le traitement du taux sérique élevé d’acide urique pourrait entraîner une réduction suffisante du taux d’acide urique avec une durée de traitement plus courte et des coûts moins importants. Les résultats de cette étude soutiennent le besoin d’une ressource au Fraser Health pour guider et standardiser l’utilisation de la rasburicase.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.003 | 0.008 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.001 | 0.001 |
| Bibliometrics | 0.005 | 0.008 |
| Science and technology studies | 0.001 | 0.000 |
| Scholarly communication | 0.001 | 0.001 |
| Open science | 0.001 | 0.001 |
| Research integrity | 0.001 | 0.000 |
| Insufficient payload (model declined to judge) | 0.002 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".